BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:BDSI
Previous Symbol
CUSIP09060J10
Phone919-582-9050
Debt
Debt-to-Equity Ratio1.42
Current Ratio3.00
Quick Ratio2.77
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$61.99 million
Price / Sales4.33
Cash FlowN/A
Price / CashN/A
Book Value$0.50 per share
Price / Book7.60
Profitability
EPS (Most Recent Fiscal Year)($0.39)
Net Income$5.28 million
Net Margins-85.93%
Return on Equity-141.35%
Return on Assets-30.74%
Miscellaneous
Employees116
Outstanding Shares70,710,000
Market Cap$268.69 million
OptionableOptionable
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings results on Thursday, November, 8th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The specialty pharmaceutical company earned $14.16 million during the quarter, compared to analysts' expectations of $14.21 million. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
5 equities research analysts have issued 12 month price objectives for BioDelivery Sciences International's stock. Their predictions range from $4.00 to $5.00. On average, they expect BioDelivery Sciences International's stock price to reach $4.80 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.
What is the consensus analysts' recommendation for BioDelivery Sciences International?
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. HC Wainwright analysts commented, "Our $5, 12-month price target is based on a DCF reflecting strong Belbuca growth to over $150M by 2022, cash- flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10.5% WACC discount and negative -15% terminal value beyond 2027, and includes 93M shares (post-financing, plus other currently anti-dilutive shares)." (11/2/2018)
- 2. According to Zacks Investment Research, "BioDelivery secured improved positioning in several managed care contracts providing preferred access to its two drugs, Bunavail and belbuca. This has already started to boost the drug’s sales and profitability in 2018. Meanwhile, launch of Belbuca in Canada for severe pain is also supporting sales growth. Appointment of Herm Cukier, who has a good track record of bringing growth, as its new CEO bodes well for the company. BioDelivery’s shares have outperformed the industry in the past three months. However, given the lackluster performance of Bunavail, BioDelivery decided to reduce spending on the drug. Moreover, the company’s portfolio as well as its pipeline candidates may also face severe competition as it targets a highly genericized and crowded market. Loss estimates have been mixed ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/15/2018)
- 3. Cantor Fitzgerald analysts commented, ". Post 2Q18, we are reiterating our Overweight rating and our 12-month price target of $4.50. BDSI continues to evolve into a commercial- stage company with solid growth from its lead product, Belbuca. During the quarter, Belbuca TRxs were up 80% over 2Q17, and were up 31% over 1Q18. Fundamentally, BDSI continues to perform very well, and with the financing overhang removed, a new CEO and CMO, and with strong additions to the Board, we believe that investors will be rewarded by BDSI’s solid execution in 2018 and beyond." (8/9/2018)
Has BioDelivery Sciences International been receiving favorable news coverage?
Media stories about BDSI stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include Zai Lab (ZLAB), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Alder Biopharmaceuticals (ALDR), Puma Biotechnology (PBYI), ImmunoGen (IMGN), Dicerna Pharmaceuticals (DRNA), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Kiniksa Pharmaceuticals (KNSA), Akorn (AKRX), Deciphera Pharmaceuticals (DCPH) and Y-mAbs Therapeutics (YMAB).
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Mr. Ernest Robert De Paolantonio CPA, MBA, CFO, Corp. Sec. & Treasurer (Age 65)
- Mr. Herm Cukier, CEO & Director (Age 52)
- Mr. Scott M. Plesha, Pres (Age 54)
- Mr. Joseph M. Lockhart, Sr. VP of Operations
- Ms. Mary Coleman, VP of Investor & PR
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (6.10%), Point72 Asset Management L.P. (2.12%), Foresite Capital Management II LLC (1.34%), Blair William & Co. IL (1.11%), Foresite Capital Management III LLC (0.89%) and Fosun International Ltd (0.93%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De and Samuel P Sears, Jr. View Institutional Ownership Trends for BioDelivery Sciences International.
Which institutional investors are selling BioDelivery Sciences International stock?
BDSI stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Hikari Power Ltd and Renaissance Technologies LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.
Which institutional investors are buying BioDelivery Sciences International stock?
BDSI stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Foresite Capital Management II LLC, Point72 Asset Management L.P., Foresite Capital Management III LLC, Fosun International Ltd, Essex Investment Management Co. LLC, Alpha Omega Wealth Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for BioDelivery Sciences International.
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $3.80.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $268.69 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.
What is BioDelivery Sciences International's official website?
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
